1737-01-5

Basic information

• Product Name: 3-Fluor-1-β-nitropropenyl-benzol
• CAS NO: 1737-01-5
• Molecular Weight: 181.166
• Mol File: 1737-01-5.mol

Chemical Properties

• Boiling Point: 262.2±15.0 °C(Predicted)
• Density: 1.230±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-Fluor-1-β-nitropropenyl-benzol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Fluor-1-β-nitropropenyl-benzol(1737-01-5)
• EPA Substance Registry System: 3-Fluor-1-β-nitropropenyl-benzol(1737-01-5)

Safety Data

• Hazardous Substances Data: 1737-01-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Fluor-1-β-nitropropenyl-benzol is utilized as a precursor in the synthesis of various pharmaceuticals. Its unique structure allows it to be a key intermediate in the production of drugs with specific therapeutic properties.
Used in Organic Compounds Synthesis:
In addition to pharmaceuticals, 3-Fluor-1-β-nitropropenyl-benzol serves as a precursor for the synthesis of other organic compounds. Its presence in these compounds can impart particular chemical and physical characteristics that are valuable in various applications across different industries.
Used in Chemical Research:
3-Fluor-1-β-nitropropenyl-benzol is also employed in chemical research settings, where its properties and reactions are studied to further understand organic chemistry and potentially discover new applications or compounds.
Used in Specialty Chemicals Production:
Due to its unique structure and reactivity, 3-Fluor-1-β-nitropropenyl-benzol is used in the production of specialty chemicals that have specific applications in industries such as agriculture, materials science, and manufacturing.

Upstream product

• 79-24-3 Nitroethane 
• 456-48-4 3-Fluorobenzaldehyde 

Relevant articles and documents

Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs

It has been reported that among drugs with mixed actions on central nervous system monoamine systems, increased serotonergic activity is associated with decreased potency as a reinforcer. The present experiment was designed to examine this relationship for amphetamine analogs that varied in serotonin releasing potency and to evaluate whether serotonergic actions can affect reinforcing efficacy. Compounds PAL 313 and 314 are para- and meta-methylamphetamine, respectively. PAL 303 and 353 are para- and meta-fluoroamphetamine, respectively. All compounds had similar potencies as in vitro releasers of dopamine (DA) and norepinephrine (NE) but differed in potency for 5-hydroxytryptamine (serotonin) (5-HT) release [EC50 (nanomolar) PAL 313 = 53.4; PAL 314 = 218; PAL 303 = 939; PAL 353 = 1937]. When made available to rhesus monkeys (Macaca mulatta) (n = 4) for self-administration under a fixed-ratio 25 schedule, all were positive reinforcers with biphasic dose-response functions (0.003-1.0 mg/kg) and were equipotent. PAL 313 was self-administered at a lower rate than the other compounds, which were indistinguishable. Under a progressive-ratio schedule (n = 5), all drugs were positive reinforcers. Dose-response functions increased to a maximum or were biphasic (0.01-1.0 mg/kg), and drugs were equipotent. At maximum, PAL 313 maintained less responding than ther PAL drugs, which maintained similar maxima. Thus, all compounds were positive reinforcers under both schedules, consistent with their potent DA actions. Responding was lower when 5-HT potency was higher and comparable with DA and NE potency. The results suggest that the mechanism for this effect involves a decrease in reinforcing potency and efficacy among monoamine releasing agents when 5-HT releasing potency is increased relative to DA.